Zo Sungmin, Choe Junsu, Kim Dae Hun, Kim Su-Young, Jhun Byung Woo
Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, South Korea.
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Antimicrob Agents Chemother. 2024 Dec 5;68(12):e0105524. doi: 10.1128/aac.01055-24. Epub 2024 Oct 29.
Despite guideline-based therapy, some patients with complex pulmonary disease (MAC-PD) experience treatment failure. We analyzed the clinical courses of 271 patients with treatment-refractory MAC-PD who discontinued therapy after at least 12 months. Patients were categorized into two groups-the retreatment group, who resumed antibiotics due to clinical or radiological deterioration, and the stable group, who did not require antibiotics. Of the study patients, 138 (51%) were in the retreatment group, whereas 133 (49%) were in the stable group. In the multivariate analysis models, an elevated erythrocyte sedimentation rate (adjusted hazard ratio [aHR] =1.01), the presence of a cavity (aHR = 1.75), and the number of lobes affected by bronchiectasis (aHR = 1.21) were associated with the need for retreatment. Our data indicated that approximately 50% of the patients with refractory MAC-PD who discontinued antibiotics eventually required retreatment, which was influenced by the extent of lung destruction or inflammation. These findings can aid in determining treatment strategies for patients with refractory diseases.
尽管采用了基于指南的治疗方法,但一些患有复杂性肺部疾病(MAC-PD)的患者仍经历治疗失败。我们分析了271例治疗难治性MAC-PD患者的临床病程,这些患者在至少12个月后停止治疗。患者被分为两组——再治疗组,因临床或影像学恶化而重新使用抗生素;稳定组,不需要使用抗生素。在研究患者中,138例(51%)在再治疗组,而133例(49%)在稳定组。在多变量分析模型中,红细胞沉降率升高(调整后风险比[aHR]=1.01)、存在空洞(aHR = 1.75)以及受支气管扩张影响的肺叶数量(aHR = 1.21)与再治疗需求相关。我们的数据表明,约50%停用抗生素的难治性MAC-PD患者最终需要再治疗,这受到肺破坏或炎症程度的影响。这些发现有助于为难治性疾病患者确定治疗策略。